2.09
4.13%
-0.09
Vorhandelsmarkt:
2.10
0.01
+0.48%
Schlusskurs vom Vortag:
$2.18
Offen:
$2.21
24-Stunden-Volumen:
121.70K
Relative Volume:
0.07
Marktkapitalisierung:
$9.07M
Einnahmen:
$79,300
Nettoeinkommen (Verlust:
$-6.92M
KGV:
-0.1101
EPS:
-18.9818
Netto-Cashflow:
$-5.34M
1W Leistung:
-8.73%
1M Leistung:
+19.43%
6M Leistung:
+78.63%
1J Leistung:
+99.05%
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Firmenname
Virax Biolabs Group Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie VRAX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
2.09 | 9.07M | 79,300 | -6.92M | -5.34M | -18.98 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virax Biolabs Group Ltd Aktie (VRAX) Neueste Nachrichten
Cosmos Health secures exclusive distribution agreement with Virax Biolabs - Yahoo Finance
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Lelezard
Virax Biolabs Group Ltd (VRAX) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December - Defense World
Virax Biolabs Achieves Shareholder Approvals at Adjourned Annual Meeting - TipRanks
Stock Region Signal Report - substack.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Virax Biolabs Announces Strategic Goals and Developments for 2025 - TipRanks
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect across the European Union, Norway, and Switzerland - Marketscreener.com
Virax Biolabs Expands ImmuneSelect Reach in Europe - TipRanks
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland - Yahoo Finance
Virax Biolabs Group First Half 2025 Earnings: US$0.89 loss per share (vs US$1.64 loss in 1H 2024) - Simply Wall St
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Virax Biolabs Group Ltd - GuruFocus.com
Virax Biolabs announces 2024 annual meeting - Investing.com India
Virax Biolabs announces 2024 annual meeting By Investing.com - Investing.com UK
Virax Biolabs Sets Date for 2024 AGM - TipRanks
Virax Biolabs announces distribution agreement with Europa Biosite - TipRanks
Virax Biolabs Expands Reach with Europa Biosite Deal - TipRanks
EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland - Yahoo Finance
Pre-market Movers: ALZN, VRAX, APDN, LQDA... - RTTNews
Analyzing the Impact of Earnings Reports on Virax Biolabs Group Ltd Inc. (VRAX) Price Performance - The InvestChronicle
Daily Progress: Virax Biolabs Group Ltd (VRAX) Gain 14.20, Closing at 1.85 - The Dwinnex
Virax Biolabs Plans New Share Offering - TipRanks
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 72.2% in September - Defense World
Charting the Course: Virax Biolabs Group Ltd’s VRAX Stock Prospects - The InvestChronicle
How did Virax Biolabs Group Ltd (VRAX) fare last session? - US Post News
Daily Market Movement: Virax Biolabs Group Ltd (VRAX) Sees a -3.56 Decrease, Closing at 2.44 - The Dwinnex
Virax Biolabs Group Ltd (VRAX)’s Day in Review: Closing at 2.84, Up by 9.65 - The Dwinnex
Virax Biolabs Group Ltd Inc. (VRAX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
A closer look at VRAX’s price-to-free cash flow ratio - US Post News
Cosmos Health expands mpox kit distribution to Gulf States - Investing.com India
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar - Lelezard
Ratios Reveal: Breaking Down Virax Biolabs Group Ltd (VRAX)’s Financial Health - The Dwinnex
VRAX’s 2023 Market Dance: Up 140.41% – Time to Invest? - The InvestChronicle
Investing in Virax Biolabs Group Ltd (VRAX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Closing Figures Unveiled: Virax Biolabs Group Ltd (VRAX) Drop -12.90, Closes at 3.51 - The Dwinnex
Virax Biolabs Group Ltd (VRAX) requires closer examination - US Post News
Post-Trade Analysis: Virax Biolabs Group Ltd (VRAX) Slides -7.91, Closing at 4.66 - The Dwinnex
Virax Biolabs Group Ltd (VRAX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Luminar Technologies Inc (NASDAQ: LAZR) Shares Look Bullish In 2024 - Stocks Register
NuCana halts NuTide:323 study on colorectal cancer - Investing.com
NuCana halts NuTide:323 study on colorectal cancer By Investing.com - Investing.com Australia
Virax Biolabs to Participate at 7th European Congress of Immunology - Quantisnow
Wall Street-Heavily Traded - WDRB
Russia bans entry to dozens of American journalists, including WSJ, NYT and Washington Post - CNN International
Virax stock soars on Mpox tests deal in Europe and Middle East - Invezz
Finanzdaten der Virax Biolabs Group Ltd-Aktie (VRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):